Idiopathic Pulmonary Fibrosis Market

Table of Content

SECTION I: REPORT OVERVIEW

1. PREFACE
1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY
2.1. Chapter Overview
2.2. Research Assumptions

2.3. Database Building
2.3.1. Data Collection
2.3.2. Data Validation
2.3.3. Data Analysis

2.4. Project Methodology
2.4.1. Secondary Research
2.4.1.1. Annual Reports
2.4.1.2. Academic Research Papers
2.4.1.3. Company Websites
2.4.1.4. Investor Presentations
2.4.1.5. Regulatory Filings
2.4.1.6. White Papers
2.4.1.7. Industry Publications
2.4.1.8. Conferences and Seminars
2.4.1.9. Government Portals
2.4.1.10. Media and Press Releases
2.4.1.11. Newsletters
2.4.1.12. Industry Databases
2.4.1.13. Roots Proprietary Databases
2.4.1.14. Paid Databases and Sources
2.4.1.15. Social Media Portals
2.4.1.16. Other Secondary Sources

2.4.2. Primary Research
2.4.2.1. Introduction

2.4.2.2. Types
2.4.2.2.1. Qualitative
2.4.2.2.2. Quantitative

2.4.2.3. Advantages

2.4.2.4. Techniques
2.4.2.4.1. Interviews
2.4.2.4.2. Surveys
2.4.2.4.3. Focus Groups
2.4.2.4.4. Observational Research
2.4.2.4.5. Social Media Interactions

2.4.2.5. Stakeholders
2.4.2.5.1. Company Executives (CXOs)
2.4.2.5.2. Board of Directors
2.4.2.5.3. Company Presidents and Vice Presidents
2.4.2.5.4. Key Opinion Leaders
2.4.2.5.5. Research and Development Heads
2.4.2.5.6. Technical Experts
2.4.2.5.7. Subject Matter Experts
2.4.2.5.8. Scientists
2.4.2.5.9. Doctors and Other Healthcare Providers

2.4.2.6. Ethics and Integrity
2.4.2.6.1. Research Ethics
2.4.2.6.2. Data Integrity

2.4.3. Analytical Tools and Databases

3. MARKET DYNAMICS
3.1. Forecast Methodology
3.1.1. Top-Down Approach
3.1.2. Bottom-Up Approach
3.1.3. Hybrid Approach

3.2. Market Assessment Framework
3.2.1. Total Addressable Market (TAM)
3.2.2. Serviceable Addressable Market (SAM)
3.2.3. Serviceable Obtainable Market (SOM)
3.2.4. Currently Acquired Market (CAM)

3.3. Forecasting Tools and Techniques
3.3.1. Qualitative Forecasting
3.3.2. Correlation
3.3.3. Regression
3.3.4. Time Series Analysis
3.3.5. Extrapolation
3.3.6. Convergence
3.3.7. Forecast Error Analysis
3.3.8. Data Visualization
3.3.9. Scenario Planning
3.3.10. Sensitivity Analysis

3.4. Key Considerations
3.4.1. Demographics
3.4.2. Market Access
3.4.3. Reimbursement Scenarios
3.4.4. Industry Consolidation

3.5. Robust Quality Control
3.6. Key Market Segmentations
3.7. Limitations

4. MACRO-ECONOMIC INDICATORS
4.1. Chapter Overview
4.2. Market Dynamics

4.2.1. Time Period
4.2.1.1. Historical Trends
4.2.1.2. Current and Forecasted Estimates

4.2.2. Currency Coverage
4.2.2.1. Overview of Major Currencies Affecting the Market
4.2.2.2. Impact of Currency Fluctuations on the Industry

4.2.3. Foreign Exchange Impact
4.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
4.2.3.2. Strategies for Mitigating Foreign Exchange Risk

4.2.4. Recession
4.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
4.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

4.2.5. Inflation
4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
4.2.5.2. Potential Impact of Inflation on the Market Evolution

4.2.6. Interest Rates
4.2.6.1. Overview of Interest Rates and Their Impact on the Market
4.2.6.2. Strategies for Managing Interest Rate Risk

4.2.7. Commodity Flow Analysis
4.2.7.1. Type of Commodity
4.2.7.2. Origins and Destinations
4.2.7.3. Values and Weights
4.2.7.4. Modes of Transportation

4.2.8. Global Trade Dynamics
4.2.8.1. Import Scenario
4.2.8.2. Export Scenario

4.2.9. War Impact Analysis
4.2.9.1. Russian-Ukraine War
4.2.9.2. Israel-Hamas War

4.2.10. COVID Impact / Related Factors
4.2.10.1. Global Economic Impact
4.2.10.2. Industry-specific Impact
4.2.10.3. Government Response and Stimulus Measures
4.2.10.4. Future Outlook and Adaptation Strategies

4.2.11. Other Indicators
4.2.11.1. Fiscal Policy
4.2.11.2. Consumer Spending
4.2.11.3. Gross Domestic Product (GDP)
4.2.11.4. Employment
4.2.11.5. Taxes
4.2.11.6. R&D Innovation
4.2.11.7. Stock Market Performance
4.2.11.8. Supply Chain
4.2.11.9. Cross-Border Dynamics

SECTION II: QUALITATIVE INSIGHTS

5. EXECUTIVE SUMMARY

6. INTRODUCTION
6.1. Chapter Overview
6.2. Overview of Idiopathic Pulmonary Fibrosis
6.2.1. Types of Idiopathic Pulmonary Fibrosis Drug Class
6.2.2. Benefits of the Idiopathic Pulmonary Fibrosis Drugs
6.2.3. Side-Effects Associated with Idiopathic Pulmonary Fibrosis Drugs

6.3. Future Perspective

7. REGULATORY SCENARIO

SECTION III: MARKET OVERVIEW

8. COMPREHENSIVE DATABASE OF LEADING PLAYERS

9. COMPETITIVE LANDSCAPE
9.1. Chapter Overview
9.2. Idiopathic Pulmonary Fibrosis: Overall Market Landscape
9.2.1. Analysis by Year of Establishment
9.2.2. Analysis by Company Size
9.2.3. Analysis by Location of Headquarters

9.2.4. Idiopathic Pulmonary Fibrosis: Overall Market Landscape
9.2.4.1. Analysis by Drug Type
9.2.4.2. Analysis by Mode of Action
9.2.4.3. Analysis by Route of Administration
9.2.4.4. Analysis by Treatment Type
9.2.4.5. Analysis by Distribution Channel

10. PORTER'S FIVE FORCES ANALYSIS

11. COMPETITIVE COMPETITIVENESS ANALYSIS

12. STARTUP ECOSYSTEM IN THE IDIOPATHIC PULMONARY FIBROSIS MARKET
12.1. Idiopathic Pulmonary Fibrosis: Market Landscape of Startups
12.1.1. Analysis by Year of Establishment
12.1.2. Analysis by Company Size
12.1.3. Analysis by Company Size and Year of Establishment
12.1.4. Analysis by Location of Headquarters
12.1.5. Analysis by Company Size and Location of Headquarters
12.1.6. Analysis by Ownership Structure

12.2. Key Findings

SECTION IV: COMPANY PROFILES

13. COMPANY PROFILES
13.1. Chapter Overview
13.2. Alembic Pharmaceuticals
13.2.1. Company Overview
13.2.2. Company Mission
13.2.3. Company Footprint
13.2.4. Management Team
13.2.5. Contact Details
13.2.6. Financial Performance
13.2.7. Operating Business Segments
13.2.8. Drugs Pipeline Portfolio
13.2.9. MOAT Analysis
13.2.10. Recent Developments and Future Outlook

* similar detail is presented for other below mentioned companies based on information in the public domain

13.3. AstraZeneca
13.4. Biogen
13.5. Boehringer Ingelheim GMBH
13.6. Bristol Myers Squibb Company
13.7. Celix Pharma
13.8. Cipla
13.9. Daewoong Pharmaceutical
13.10. F. Hoffmann La Roche
13.11. FibroGen
13.12. Galapagos NV
13.13. Galecto Biotech
13.14. GNI Group
13.15. Horizon Therapeutics
13.16. Intas Pharmaceuticals
13.17. Johnson & Johnson Services
13.18. Jubilant Pharmova
13.19. Medicinova
13.20. Neopharm Group
13.21. Novartis AG
13.22. Pfizer

SECTION V: MARKET TRENDS

14. PATENT ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology

14.3. Idiopathic Pulmonary Fibrosis: Patent Analysis
14.3.1. Analysis by Patent Publication Year
14.3.2. Analysis by Type of Patent and Patent Publication Year
14.3.3. Analysis by Patent Application Year
14.3.4. Analysis by Patent Jurisdiction
14.3.5. Analysis by CPC Symbols
14.3.6. Analysis by Type of Applicant
14.3.7. Leading Industry Players: Analysis by Number of Patents
14.3.8. Leading Individual Assignees: Analysis by Number of Patents

15. PARTNERSHIPS AND COLLABORATIONS
15.1. Chapter Overview
15.2. Partnership Models

15.3. Idiopathic Pulmonary Fibrosis: Partnerships and Collaborations
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.3. Analysis by Year and Type of Partnership
15.3.4. Analysis by Type of Partner
15.3.5. Analysis by Location of Headquarters of Partner
15.3.6. Analysis by Type of Partnership and Location of Headquarters of Partner
15.3.7. Most Active Players: Analysis by Number of Partnerships

15.3.8. Regional Analysis
15.3.8.1. Intercontinental and Intracontinental Deals
15.3.8.2. Local and International Deals

16. GRANT ANALYSIS
16.1. Chapter Overview
16.2. Scope and Methodology

16.3. Idiopathic Pulmonary Fibrosis: Grant Analysis
16.3.1. Analysis by Year of Grant Award
16.3.2. Analysis by Amount Awarded
16.3.3. Analysis by Support Period
16.3.4. Analysis by Support Period and Funding Institute Center
16.3.5. Analysis by Type of Grant Application
16.3.6. Analysis by Purpose of Grant Award
16.3.7. Analysis By Activity Code
16.3.8. Analysis by NIH Spending Category
16.3.9. Analysis by Study Section Involved
16.3.10. Popular NIH Departments: Analysis by Number of Grants
16.3.11. Analysis by Type of Recipient Organization
16.3.12. Prominent Program Officers: Analysis by Number of Grants
16.3.13. Popular Recipient Organizations: Analysis by Number of Grants
16.3.14. Popular Recipient Organizations: Analysis by Grant Amount
16.3.15. Analysis by Region of Recipient Organizations

17. FUNDING AND INVESTMENTS ANALYSIS
17.1. Funding Models
17.2. Idiopathic Pulmonary Fibrosis: Funding and Investments
17.2.1. Analysis by Year of Funding
17.2.2. Analysis of Funding Instances by Type of Funding
17.2.3. Analysis of Funding Instances by Year and Type of Funding
17.2.4. Analysis of Amount Invested by Type of Funding
17.2.5. Analysis of Funding Instances by Country
17.2.6. Most Active Players: Analysis by Amount Raised

17.3. Summary and Key Takeaways

18. CLINICAL TRIAL ANALYSIS
18.1. Analysis Methodology and Key Parameters
18.2. Idiopathic Pulmonary Fibrosis: Clinical Trial Analysis
18.2.1. Analysis by Trial Status
18.2.2. Analysis by Trial Registration Year
18.2.3. Analysis by Type of Sponsor / Collaborator
18.2.4. Analysis by Type of Study Design
18.2.5. Analysis by Registration Year and Type of Study
18.2.6. Analysis by Patient Enrollment
18.2.7. Year-wise Trend of Completed and Recruiting Trials
18.2.8. Analysis by Age Category
18.2.9. Word Cloud of Study Titles
18.2.10. Most Active Industry Players: Analysis by Number of Registered Trials
18.2.11. Most Active Non- Industry Players: Analysis by Number of Registered Trials
18.2.12. Analysis by Trial Location
18.2.13. Analysis by Trial Status and Geography

SECTION VI: MARKET OPPORTUNITY ANALYSIS

19. GLOBAL IDIOPATHIC PULMONARY FIBROSIS MARKET
19.1. Chapter Overview
19.2. Key Assumptions and Methodology
19.3. Trends Disruption Impacting Market
19.4. Demand Side Trends
19.5. Supply Side Trends
19.6. Global Idiopathic Pulmonary Fibrosis Market, Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

19.7. Multivariate Scenario Analysis
19.7.1. Conservative Scenario
19.7.2. Optimistic Scenario

19.8. Investment Feasibility Index
19.9. Key Market Segmentations

20. MARKET OPPORTUNITIES BASED ON TYPE OF DRUG
20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Revenue Shift Analysis
20.4. Market Movement Analysis
20.5. Penetration-Growth (P-G) Matrix
20.6. Idiopathic Pulmonary Fibrosis Market for Nintedanib: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.7. Idiopathic Pulmonary Fibrosis Market for Pirfenidone: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
20.8. Idiopathic Pulmonary Fibrosis Market for Other Drug Types: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

20.9. Data Triangulation and Validation
20.9.1. Secondary Sources
20.9.2. Primary Sources
20.9.3. Statistical Modeling

21. MARKET OPPORTUNITIES BASED ON MODE OF ACTION
21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Revenue Shift Analysis
21.4. Market Movement Analysis
21.5. Penetration-Growth (P-G) Matrix
21.6. Idiopathic Pulmonary Fibrosis Market for Antifibrotic Agents: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.7. Idiopathic Pulmonary Fibrosis Market for Tyrosine Kinase Inhibitors: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
21.8. Idiopathic Pulmonary Fibrosis Market for Other Modes of Action: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

21.9. Data Triangulation and Validation
21.9.1. Secondary Sources
21.9.2. Primary Sources
21.9.3. Statistical Modeling

22. MARKET OPPORTUNITIES BASED ON ROUTE OF ADMINISTRATION
22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Revenue Shift Analysis
22.4. Market Movement Analysis
22.5. Penetration-Growth (P-G) Matrix
22.6. Idiopathic Pulmonary Fibrosis Market for Oral: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
22.7. Idiopathic Pulmonary Fibrosis Market for Injectables: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

22.8. Data Triangulation and Validation
22.8.1. Secondary Sources
22.8.2. Primary Sources
22.8.3. Statistical Modeling

23. MARKET OPPORTUNITIES BASED ON TYPE OF TREATMENT
23.1. Chapter Overview
23.2. Key Assumptions and Methodology
23.3. Revenue Shift Analysis
23.4. Market Movement Analysis
23.5. Penetration-Growth (P-G) Matrix
23.6. Idiopathic Pulmonary Fibrosis Market for Oxygen Therapy: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.7. Idiopathic Pulmonary Fibrosis Market for Lung Transplant: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
23.8. Idiopathic Pulmonary Fibrosis Market for Others: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

23.9. Data Triangulation and Validation
23.9.1. Secondary Sources
23.9.2. Primary Sources
23.9.3. Statistical Modeling

24. MARKET OPPORTUNITIES BASED ON DISTRIBUTION CHANNEL
24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Revenue Shift Analysis
24.4. Market Movement Analysis
24.5. Penetration-Growth (P-G) Matrix
24.6. Idiopathic Pulmonary Fibrosis Market for Hospitals Pharmacies: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.7. Idiopathic Pulmonary Fibrosis Market for Retail Pharmacies: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
24.8. Idiopathic Pulmonary Fibrosis Market for Other Pharmacies: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

24.9. Data Triangulation and Validation
24.9.1. Secondary Sources
24.9.2. Primary Sources
24.9.3. Statistical Modeling

25. MARKET OPPORTUNITIES FOR IDIOPATHIC PULMONARY FIBROSIS IN NORTH AMERICA
25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Revenue Shift Analysis
25.4. Market Movement Analysis
25.5. Penetration-Growth (P-G) Matrix

25.6. Idiopathic Pulmonary Fibrosis Market in North America: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.6.1. Idiopathic Pulmonary Fibrosis Market in the US: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.6.2. Idiopathic Pulmonary Fibrosis Market in Canada: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
25.6.3. Idiopathic Pulmonary Fibrosis Market in Mexico: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

25.7. Data Triangulation and Validation

26. MARKET OPPORTUNITIES FOR IDIOPATHIC PULMONARY FIBROSIS IN EUROPE
26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Revenue Shift Analysis
26.4. Market Movement Analysis
26.5. Penetration-Growth (P-G) Matrix

26.6. Idiopathic Pulmonary Fibrosis Market in Europe: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.6.1. Idiopathic Pulmonary Fibrosis Market in Germany: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.6.2. Idiopathic Pulmonary Fibrosis Market in France: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.6.3. Idiopathic Pulmonary Fibrosis Market in Italy: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.6.4. Idiopathic Pulmonary Fibrosis Market in Spain: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.6.5. Idiopathic Pulmonary Fibrosis Market in the UK: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
26.6.6. Idiopathic Pulmonary Fibrosis Market in Rest of the Europe: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

26.7. Data Triangulation and Validation

27. MARKET OPPORTUNITIES FOR IDIOPATHIC PULMONARY FIBROSIS IN ASIA-PACIFIC
27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. R7venue Shift Analysis
27.4. Market Movement Analysis
27.5. Penetration-Growth (P-G) Matrix

27.6. Idiopathic Pulmonary Fibrosis Market in Asia-Pacific: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.6.1. Idiopathic Pulmonary Fibrosis Market in China: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.6.2. Idiopathic Pulmonary Fibrosis Market in India: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.6.3. Idiopathic Pulmonary Fibrosis Market in Japan: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.6.4. Idiopathic Pulmonary Fibrosis Market in South Korea: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
27.6.5. Idiopathic Pulmonary Fibrosis Market in Rest of the Asia-Pacific: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)

27.7. Data Triangulation and Validation

28. MARKET OPPORTUNITIES FOR IDIOPATHIC PULMONARY FIBROSIS IN REST OF THE WORLD
28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Revenue Shift Analysis
28.4. Market Movement Analysis
28.5. Penetration-Growth (P-G) Matrix
28.6. Idiopathic Pulmonary Fibrosis Market in Rest of the World: Historical Trends (Since 2020) and Forecasted Estimates (Till 2035)
28.7. Data Triangulation and Validation

29. ADJACENT MARKET ANALYSIS

SECTION VII: STRATEGIC TOOLS

30. KEY WINNING STRATEGIES

31. VALUE CHAIN ANALYSIS

32. ROOTS STRATEGIC RECOMMENDATIONS

SECTION VIII: OTHER EXCLUSIVE INSIGHTS

33. INSIGHTS FROM PRIMARY RESEARCH

34. REPORT CONCLUSION

SECTION IX: APPENDIX

35. TABULATED DATA

36. LIST OF COMPANIES AND ORGANIZATIONS

37. CUSTOMIZATION OPPORTUNITIES

38. ROOTS SUBSCRIPTION SERVICES

39. AUTHOR DETAILS